A Phase 1, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TRL345 in Healthy Volunteers
Latest Information Update: 25 Nov 2024
At a glance
- Drugs TRL 345 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Trellis Bioscience
- 21 Nov 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Dec 2024.
- 21 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2023 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.